PharmaCyte Biotech, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2022, compared with fiscal 2021. Although the request metadata identifies “2021 Q4,” this is an annual report for fiscal 2022, not a standalone quarterly filing. The company is a pre-revenue biotechnology developer using its Cell-in-a-Box live-cell encapsulation technology.
Business context and development
The lead program is CypCaps with low-dose ifosfamide for locally advanced, inoperable pancreatic cancer (LAPC). Other programs address malignant ascites and diabetes. The cannabis program is paused pending progress on the LAPC program and clinical validation of the platform.
The FDA placed the LAPC IND on clinical hold in October 2020. The company reports completing product stability work and several other requested studies, while additional compatibility, documentation and biocompatibility work remained underway. A pig study began July 21, 2022, after fiscal year-end; the planned larger study could be delayed by supply-chain issues. The company had not commenced the planned LAPC trial as of the report.
Financial performance and liquidity
| Metric | FY ended April 30, 2022 | FY ended April 30, 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $690,937 | $916,249 |
| Total operating expenses / operating loss | $4,392,014 | $3,622,981 |
| Other income, net | $152,853 | $71,745 |
| Net loss | $4,239,161 | $3,551,236 |
| Basic and diluted loss per share | $0.27 | $2.45 |
| Net cash used in operating activities | $4,117,319 | $3,330,889 |
| Cash and cash equivalents at year-end | $85,400,656 | $2,202,106 |
| Working capital | Approximately $84.8 million | Approximately $1.6 million |
| Total assets | $90,624,136 | $7,404,229 |
| Total liabilities | $704,370 | $724,778 |
Operating expenses rose 21% year over year, primarily from higher compensation, legal and professional, and consulting costs; R&D expense declined 25%. Net loss widened by approximately $688,000. Gross margin is not applicable because the company reported no revenue.
Financing activities provided $87.3 million in FY2022, mainly from stock offerings and warrant exercises, compared with $4.6 million in FY2021. The company reported no investing cash flow. Year-end liabilities were mainly accounts payable and accrued expenses; the filing does not identify material outstanding borrowings at April 30, 2022.
Material changes, outlook and risks
- Capital and dilution: FY2022 financing substantially increased cash but included significant equity and warrant issuances. At year-end, 10.77 million warrants were outstanding, including warrants exercisable at relatively low prices. Future exercises or financings may dilute shareholders.
- Regulatory and clinical uncertainty: Lifting the FDA clinical hold is uncertain, and the FDA may request further work or require a different clinical-trial phase. Historical European studies were small, non-randomized and not statistically conclusive; their results may not be accepted or reproduced.
- Manufacturing concentration: Austrianova is the sole identified manufacturer for the encapsulation technology. The company cites supply-chain delays and possible Austrianova liquidity issues, with no known replacement manufacturer.
- Other programs: Malignant-ascites preclinical work began in May 2022; a future Phase 1 trial depends on successful results and FDA authorization. Diabetes research on Melligen cells has not produced expected results, and alternative research partnerships were still being negotiated.
- Operating outlook: No revenue or earnings guidance was provided. Management expects continuing development costs and losses and may require additional capital over time. COVID-19, supply disruption, trial delays, competition and limited staffing remain risks.
- Controls and governance: Management concluded disclosure controls were ineffective due to a material weakness involving insufficient segregation of the CFO’s duties; it planned remediation during FY2023. A prior IT-control weakness was reported as remediated. The company also disclosed a potential activist-shareholder proxy contest.
- Audit and contingencies: The auditor gave an unqualified opinion on the financial statements and reported no critical audit matters. The filing reports no material pending litigation. A share-repurchase program of up to $10 million was authorized after year-end; approximately $2.1 million had been spent by July 28, 2022.
Most important facts for investors to verify
- Current FDA clinical-hold status, remaining response requirements, and whether the FDA will permit the LAPC trial to begin.
- Completion, results, cost and timing of the pig study and remaining capsule/device compatibility and biocompatibility work.
- Cash use after April 30, 2022, expected operating runway, and whether the stated capital supports planned studies without further financing.
- Austrianova’s manufacturing capacity and financial condition, and availability of contingency manufacturing arrangements.
- Warrant and pre-funded-warrant balances, exercise proceeds, potential dilution, and subsequent share-count changes.
- Progress in remediating the CFO-duty segregation weakness and any changes in control effectiveness.
- Whether the post-year-end repurchases and executive equity awards affect liquidity, share count or shareholder approval requirements.